Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Medtronic
Baxter
Johnson and Johnson
Accenture
McKesson
Merck
Daiichi Sankyo

Generated: July 23, 2018

DrugPatentWatch Database Preview

AZILSARTAN KAMEDOXOMIL - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for azilsartan kamedoxomil and what is the scope of azilsartan kamedoxomil freedom to operate?

Azilsartan kamedoxomil
is the generic ingredient in two branded drugs marketed by Arbor Pharms Llc and is included in two NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Azilsartan kamedoxomil has eighty patent family members in thirty-four countries.

There are six drug master file entries for azilsartan kamedoxomil. One supplier is listed for this compound.
Summary for AZILSARTAN KAMEDOXOMIL
International Patents:80
US Patents:4
Tradenames:2
Applicants:1
NDAs:2
Drug Master File Entries: 6
Suppliers / Packagers: 1
Bulk Api Vendors: 54
Patent Applications: 143
DailyMed Link:AZILSARTAN KAMEDOXOMIL at DailyMed
Pharmacology for AZILSARTAN KAMEDOXOMIL
Synonyms for AZILSARTAN KAMEDOXOMIL
863031-24-7
AC-26396
AKOS025401854
Azilsartan kamedoxomil (USAN)
CHEBI:68847
CHEMBL2103795
D08865
DTXSID70235483
FT-0686729
potassium 3-{4'-[(2-ethoxy-7-{[(5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy]carbonyl}-1H-benzimidazol-1-yl)methyl]biphenyl-2-yl}-5-oxo-1,2,4-oxadiazol-4-ide
SCHEMBL967310
TAK-491
UNII-WEC6I2K1FC
WEC6I2K1FC

US Patents and Regulatory Information for AZILSARTAN KAMEDOXOMIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-002 Dec 20, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Arbor Pharms Llc EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for AZILSARTAN KAMEDOXOMIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 ➤ Sign Up ➤ Sign Up
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 ➤ Sign Up ➤ Sign Up
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 ➤ Sign Up ➤ Sign Up
Arbor Pharms Llc EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for AZILSARTAN KAMEDOXOMIL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,875,637 Benzimidazole derivative and use as a II receptor antagonist ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for AZILSARTAN KAMEDOXOMIL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/028 United Kingdom ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C0034 France ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/735/001 20111207
0120004 00052 Estonia ➤ Sign Up PRODUCT NAME: EDARBI - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9280 FINAL 07.12.2011
962 Luxembourg ➤ Sign Up 91962, EXPIRES: 20261207
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Deloitte
Citi
Argus Health
Colorcon
Baxter
Johnson and Johnson
Cerilliant
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.